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ABSTRACT 
 
Colorectal cancer is the second most common cancer in women and the third most common cancer in 
men worldwide, with 1.8 million new cases and almost 861000 deaths in 2018. Approximately 5–10% 
of the annual colorectal cancer burden can be attributed to inherited high risk germline mutations. The 
most common inherited colon cancer syndrome is Lynch syndrome, which accounts for up to 5% of 
all CRCs. Lynch syndrome displays both genotypic and phenotypic heterogeneity and can be 
suspected on the basis of a strong family history of colorectal- or endometrial cancer, but also of other 
tumors. Genetic counselling is recommended for families with Lynch syndrome, to provide the patient 
and family members with information about cancers risk and options for surveillance and 
management.  
In paper I we compared disease associated haplotypes in families from Sweden, Germany and 
France, all carrying the MLH1 mutation c.2059C>T, in order to elucidate if this is a founder 
mutation. When analyzing the haplotype in the families with Swedish descent, a shared region of 
approximately 0.9–2.8 Mb was identified. The MLH1 c.2059C>T mutation thus act as a founder in the 
Swedish population, but is also found in Europe, Asia and Australia, indicating that this is a recurring 
mutation globally albeit with a very low allele frequency.  
 In paper II and III we investigated if genetic anticipation was part of the clinical picture in a 
Swedish cohort of Lynch syndrome families, as well as in a larger European cohort of PMS2 
mutation carriers. In paper II, a total 1003 proven mutation carriers from 239 families with Lynch 
syndrome were included. An anticipation effect of 2,55 years and hazard rate of 1.33 between 
generations was seen in families with MSH2 mutation. In addition, an anticipation effect of 7.33 years 
and a hazard ration of 1.86 per generation was shown in families with PMS2 mutation. In paper III, 
637 individuals from 123 families with PMS2 mutation were recruited from Netherlands, Norway, 
Germany, Denmark, Spain, including the Swedish PMS2 patients in paper II. Participants were 
assigned mutation probabilities in cases of unknown carrier status. As opposed to the result in paper II, 
an anticipation effect initially shown in a crude analysis was no longer statistically significant when 
corrections were made for gender and birth cohort. 
In paper IV we characterized the tumor spectrum, excluding colorectal- and endometrial cancers, 
in a nationwide cohort of 235 Swedish Lynch syndrome families. Data was stratified for gender, 
primary cancer, age, and mutated gene. Relative proportions of specific cancer types were compared 
to corresponding proportions in the reference population from the national Swedish Cancer Registry. 
Individuals of both sexes in our cohort had a higher proportion of gastric cancer, small bowel cancer 
and urinary tract cancer compared to the general population. In female mutation carriers, the 
proportion of ovarian cancer and non-melanoma skin cancer was increased compared to the general 
population.  
 
 
 
Key words: Lynch syndrome, founder mutation, genetic anticipation, MSI, MLH1, MSH2, MSH6, 
PMS2  
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LIST OF ABBREVIATIONS 
 
AFAP Attenuated FAP 
BRAF v-raf murine sarcoma viral oncogene homolog B 
RB1 Retinoblastoma 1 
CIMP CpG Island Methylator Phenotype 
CIN Chromosomal Instability Pathway 
CRC Colorectal Cancer 
DCC Deleted in Colorectal Carcinoma 
DNA Deoxyribonucleic Acid 
DPC4 Deleted in Pancreatic Carcinoma 4 
EPCAM Epithelial Cell Adhesion Molecule 
FAP Familial Adenomatous Polyposis 
HNPCC Hereditary Non-Polyposis Colorectal Cancer 
KRAS Kirsten rat Sarcoma gene 
LOH Loss of Heterozygosity 
LS Lynch syndrome 
MLH1 Mut L Homolog 1 
MLH2 Mut L Homolog 2 
MMR Mismatch Repair 
MSH3 Mut S Homolog 3 
MSH6 Mut L Homolog 6 
MSI H/L Microsatellite Instability- high/low 
MUTYH Mut Y Homolog 
PCR Polymerase Chain Reaction 
PMS2 Postmeiotic Segregation 2 
TP53  Tumor Protein P53 
 
 
The names of genes are written in italics and their protein products are written in roman. 
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1  INTRODUCTION 
 
1.1 CANCER INCIDENCE 
Cancer is one of the leading causes of death and morbidity worldwide with an estimated global 
incidence of over 18 million cases in 2018, leading to over 9.5 million cancer-related deaths 
(1). In terms of incidence, cancers of the lung, female breast, and colorectum are the top three 
cancer types worldwide. In countries with rapidly growing economies a shift is seen from 
cancers related to infections or poverty, for example cancers in cervix, stomach and liver, to 
cancers that are related to a western lifestyle (2-4).  
Since the 1970s, the incidence of cancer has increased by about 40 percent in Sweden, where 
prostate cancer, breast cancer, and cancer of the colon or rectum are the most common cancer 
forms (5). Aiming at early detection of tumors, there are national screening programs for breast 
cancer and cervical cancer in Sweden. From 2019, the Swedish National Board of Health and 
Welfare recommends a nationwide screening program for colorectal cancer, something that has 
been introduced in several other developed countries (6).  
 
1.2 CANCER ETIOLOGY 
A lot of research is focused on how cancer occur, why some types of tumors are more common 
than others, or more common in some populations compared to other populations. The 
emerging picture is that lifestyle and local environmental factors interacts with rare high-risk 
genetic variants and more common, low risk genetic variants. Due to an ageing and growing 
population, as well as social and economic development in parts of the world, the global cancer 
burden is increasing. Unhealthy diets, obesity, low physical activity and smoking are 
contributing factors, in addition to improved diagnostics and screening. According to the World 
cancer research fund, over one third of the most common cancers worldwide could be 
prevented through a healthy lifestyle (1).  
Approximately 80% of all cancer occurs sporadically, as a result of normal cellular processes 
and environmental factors that constantly alter the DNA in our cells. Most of the alterations are 
repaired, however a small fraction become permanent changes in the DNA sequence (7). 
Accumulating alterations are usually randomly distributed throughout the genome, and when 
somatic mutations (tumor restricted; not present in the germline) occur in genes with potential 
to initiate or maintain tumor development, cancer might develop (8). 
In some families there appears to be more cancer than would be expected to occur by chance, 
i.e. there is a familial clustering. Shared moderate and low-penetrance genetic variants, together 
with environmental factors are thought to contribute to familial clustering, which represents 
about 10-15% of all cancer (9). The cancer risk for unaffected family members can be difficult 
to determine and various empirical models are available for this purpose (10-12).  
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In approximately 5-10% of all diagnosed cancer cases, patients have a strong family history of 
cancer caused by a well-defined hereditary cancer syndrome (9, 13). In most of the cases, the 
syndrome is caused by germline mutations inherited from parent to offspring in an autosomal 
dominant manner. Those mutations increase the risk of developing certain tumors, commonly 
with an early onset. Noteworthy, cancer is a common disease and depending on cancer type 
predominant in the family, the definition of a strong family history varies. The subject of this 
thesis is Lynch Syndrome, which is one of the most common hereditary cancer syndromes. 
Lynch Syndrome predisposes primarily for colorectal cancer (CRC) and endometrial cancer 
(EC), but also several other types of cancer.  
The difference between hereditary and sporadic cancers can be illustrated by Knudson’s two-
hit theory of tumorigenesis, a model that relies on the concept that we inherit one allele from 
each parent (14). An inherited mutation in a gene involved in maintaining genomic integrity, 
such as cell cycle regulation, suppression of growth factors or regulation of signaling pathways, 
represents a first “hit”. When a somatic mutation occurs later in life, the second hit, both alleles 
of the gene become deactivated (Fig.1). This can result in that normal cells acquire capabilities 
such as resistance to cell-death, sustaining proliferative signaling, inducing the formation of 
new blood vessels and the ability to invade neighboring tissues (15).  
 
 
 
 
 
 
 
Figure 1. Illustration of Knudson’s two-hit theory of tumorigenesis. Reprinted from S.Nowsheen, A.G. 
Georgakilas and E.S. Yang. Staying a Step Ahead of Cancer, Cancer Prevention - From Mechanisms to 
Translational Benefits (16) 2012, under the Creative Commons Attribution license (CC BY-NC-ND 4.0 
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2 MOLECULAR GENETICS 
 
The development of a tumor is a multistep process whereby an initial “gatekeeping” mutation 
enables a normal cell to outgrow the surrounding cells, by providing the cell with selective 
growth advantages (17). The process of cancer development has been compared with 
Darwinian evolution, influenced by inherited germline variants and somatic alterations 
acquired during tumor formation; new genetic changes are acquired as the cancer grows, and 
each change can contribute to new advantages for tumor formation (17).  
Studies of human breast- and colorectal tumors have indicated that most genetic variation in a 
tumor is composed of a handful frequently mutated genes, and a much larger number of genes 
mutated at a lower frequency (18). There is a vast variation in specific genetic pathways and 
genes that can be altered across different tumor types, as well as between tumor samples (19). 
The genes that underlie the driving forces of carcinogenesis are commonly divided into two 
major groups; tumor suppressor genes that are inactivated by mutations, and proto-oncogenes 
that turn into oncogenes when activated by a mutation. 
 
2.1 PROTO-ONCOGENES AND ONCOGENES 
Early studies of RNA tumor viruses revealed genes that were capable of inducing cell 
transformation, when they were transferred to normal cells (20). This discovery led to the 
identification of proto-oncogenes, a cellular counterpart that is closely related to retroviral 
oncogenes (21). Proto-oncogenes encode proteins that are involved in cell proliferating 
functions such as regulation and progression of the cell cycle, cell division and differentiation. 
A mutation in a proto-oncogene can turn the gene to an oncogene, and this “gain of function”-
mutation might lead to an increase in gene expression or render the gene constitutively active 
(e.g. producing inappropriate stimulatory signals in response to growth factors). Such an 
activating mutation act dominantly, meaning that one mutated allele usually is sufficient to 
increase the selective growth advantage of the cell. The proto-oncogenes HRAS, KRAS and 
NRAS encode the Ras protein family, which is involved in cell proliferation and cell survival. 
Those genes are among the earliest genes mutated in a variety of cancers, and act as prototypic 
oncogenes in about one-third of all human cancers (22). 
 
2.2 TUMOR SUPPRESSOR GENES   
The function of tumor suppressor genes is to protect cells from degenerating into cancer cells, 
by coding for proteins that inhibit cell proliferation. Those genes are generally involved in cell 
cycle regulation, control of apoptosis, suppression of growth factors and regulation of signaling 
pathways. When the protein product of a tumor suppressor become functionally inactivated by 
mutations, this “loss of function” promotes abnormal proliferation of tumor cells. One of the 
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first tumor suppressor genes discovered, the retinoblastoma gene (RB1) located on 
chromosome 13, was identified by studies of the rare childhood eye tumor retinoblastoma (23). 
Based on statistical studies of this tumor in children, Dr. Alfred Knudson proposed that the 
development of retinoblastoma requires loss of both functional copies of the retinoblastoma 
gene (14). While gain-of-function mutations are often dominant (as in the case of oncogenes), 
loss-of-function mutations usually are recessive. 
In the inherited form of retinoblastoma, an inherited RB1-mutation represents the first hit and 
a somatic tumor-restricted mutation represents the second hit, in accordance with Knudson’s 
two-hit theory. The second hit results in loss of the remaining wild type allele (loss of 
heterozygosity; LOH) and is commonly a result of a partial or complete chromosomal deletion 
or epigenetic silencing through hypermethylation (24) (25). The two-hit hypothesis was later 
shown to be valid also for other tumor suppressor genes (26). Another well-known tumor 
supressor gene is TP53, which is frequently inactivated in several human cancers (27). 
Interestingly, TP53 exhibit both oncogenic and tumor-suppressor functions and can have 
mutations conferring selective advantage when only one of the alleles are inactivated (28, 29). 
 
2.2.1 Gatekeepers and caretakers 
Tumor suppressor genes that are responsible for hereditary cancer syndromes can broadly be 
divided into two major categories, known as caretakers and gatekeepers (30). Gatekeepers 
normally inhibit uncontrolled cell growth by regulating cell proliferation and differentiation. 
The encoded proteins prevent cells from passing through cell cycle checkpoints, through 
arrested mitosis or induction of apoptosis (31). Several dominant hereditary cancer syndromes 
involve gatekeepers, such as the TP53 gene or the APC gene involved in familial adenomatous 
polyposis coli (FAP) discussed below (32, 33).  
While gatekeepers directly regulate tumor growth, caretakers maintain and protect the stability 
of the genome by increasing the fidelity of DNA replication and repair. Thus, caretakers 
prevent tumorigenesis more indirectly, as inactivation likely accelerate an accumulation of 
genetic changes within genes that directly affect cell proliferation and survival. Caretakers may 
sometimes be referred to as DNA stability genes or genome maintenance genes. One of all 
important caretaker systems in eukaryotes is the mismatch repair (MMR) machinery, which 
maintain genomic stability by removing mismatched nucleotides and deletion / insertion loops 
that arise during replication (34, 35). Inactivation of MMR results in an increase in the overall 
mutation rate (36). Mutations leading to loss of function of the MMR genes are central in the 
hereditary colorectal cancer syndrome Lynch syndrome (37). 
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3 CARCINOGENESIS IN COLON CANCER 
 
In the last century, several more or less overlapping models of carcinogenesis have been 
proposed in the evolving field of cancer research (15, 38). Tumors of the colon and rectum are 
highly accessible, and tissue specimens can be obtained at different stages of tumor 
development for DNA- and histopathological analysis. This enabled early studies of how 
accumulation of somatic mutations is involved in cancer development, especially in colorectal 
tumors (39, 40). Studies of families with heritable CRC syndromes further expanded the 
knowledge of molecular pathways involved in both heritable and sporadic cancer, and how 
germline mutations accelerate cancer development. The subject of this thesis is the heritable 
colorectal cancer syndrome Lynch syndrome, and therefore emphasizes the role of DNA repair 
and genome instability in cancer progression. In this context, instability refers to a range of 
genetic changes, from point mutations to larger variation such as chromosome number- or 
structure changes (41). 
According to pioneering studies by Vogelstein and coworkers in the 1980s- and 1990s, 
stepwise genetic alterations in critical genes underlies the initiation and progression of 
colorectal tumors. This early model, referred to as the adenoma-carcinoma sequence (40), 
illustrates a simplified process when normal tissue in the lining of the colon, acquires specific 
mutations and develop from hyperplastic epithelia and early adenomas into intermediate and 
late adenomas (Fig.2). In parallel with key gene mutations such as activation of oncogenes, or 
loss and gain of chromosomes, the transformation process continues into carcinoma (41). Two 
major molecular subtypes of genomic instability in CRCs have been recognized; the 
chromosomal instability (CIN) and microsatellite instability (MSI) (42, 43). These pathways 
of tumorigenesis are not mutually exclusive, and an alternative mechanism involved in 
genomic instability, the serrated/CIMP pathway, has also been presented (44, 45).  
 
3.1 CHROMOSOME INSTABILITY (CIN) PATHWAY 
Chromosomal instability (CIN) is detected in up to 85% of sporadic CRCs and represents the 
most prevalent form of genomic instability in CRC (46). As the name indicates, this pathway 
refers to a high rate of chromosome mis-segregation and involves genes that regulate 
chromosome stability at mitosis (41). The CIN pathway is characterized by changes in 
chromosome number (aneuploidy) or unbalanced structural rearrangements of chromosomes. 
A common early key mutation in the conventional adenoma–carcinoma pathway is inactivation 
of the tumor suppressor gene APC. This leads to activation of the WNT-signaling pathway, 
which is involved in e.g. proliferative and self-renewal signaling. APC is involved both in the 
hereditary CRC syndrome Familial Adenomatous Polyposis (FAP) and sporadic cancers (47). 
CIN tumors often have inactivating mutations in additional tumor suppressor genes such as 
TP53 and DCC/DPC4, and activating mutations oncogenes such as COX2 and KRAS (48). 
Other prominent genes that are involved in later stages of the adenoma–carcinoma progression 
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are SMAD2 and SMAD4. Both genes encode molecules in the transforming growth factor β 
(TGF-β) signaling pathway, which is involved in cell growth and differentiation among other 
cellular processes (Fig.2). 
 
3.2 MICROSATELLITE INSTABILITY (MSI) PATHWAY  
About 15% of the sporadic CRCs and most patients with the colorectal cancer syndrome Lynch 
syndrome can be identified with a biomarker in tumor tissue called microsatellite instability 
(MSI) (49, 50). Microsatellite DNA is short repetitive DNA stretches of 1–10 nucleotides, 
present ~100,000 times throughout the human genome (51). Microsatellite DNA is 
evolutionary relevant due to its instability, and in order not to pass damaged DNA on to 
progeny cells, several cellular repair mechanisms have evolved. One DNA proof reading 
system, the mismatch repair system (MMR), act to increase the fidelity of DNA polymerase 
by repairing slippage mistakes and nucleotide base errors at DNA replication. Deficient MMR 
results in a high rate of mutations particularly in microsatellite DNA, leading to microsatellites 
of varying lengths. Microsatellite instability have been observed in CRC, gastric cancer, and 
EC, among other cancer types (52). Mutation in the MMR genes MLH1, MSH2, MSH6 and 
PMS2 leads to MSI, which is a characteristic phenotype of most tumors associated Lynch 
syndrome, discussed below (Fig.2). MSI can also be a result from epigenetic inactivation of 
the MLH1 promotor (53). 
 
 
 
Figure 2. Conventional adenoma-to-carcinoma sequence. Reprinted with permission from De 
    Palma FDE et al., Cancers, 2019 (44). 
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3.3  THE CPG ISLAND METHYLATION (CIMP) PATHWAY  
The CpG island methylation (CIMP) pathway is responsible for the CpG island methylator 
phenotype, which is due to epigenetic instability. This pathway exhibits transcriptional 
silencing of tumor suppressor genes, including certain DNA repair genes, as a result of 
hypermethylated promoter CpG islands (54). The CIMP phenotype can be divided into 
CIMP-high and CIMP-low, based on certain thresholds of methylated markers (55). CIMP-
low tumors have been associated with a high rate of KRAS mutations, while CIMP negative 
tumors generally have a high rate of p53 mutations (56). Many CIMP-high CRC tumors 
display MSI and mutations in the BRAF gene (p.V600E), thus involving both genetic and 
epigenetics in tumorigenesis (57). The majority of those tumors are thought to arise through 
methylation-associated inactivation of MLH1 in CIMP-high sessile serrated adenomas. (58). 
The development of sporadic MSI CRC from sessile or traditional serrated adenomas is 
described by the serrated neoplasia pathway, as opposed to the classical adenoma-carcinoma 
sequence pathway in hereditary CRC displaying MSI (59).  
Definitions of the CIN, MSI and CIMP pathways not mutually exclusive, and tumors can 
occasionally exhibit features of several pathways. Both CIMP-positive tumors and MSI CRCs 
can exhibit a high degree of chromosomal aberrations, while there are CIN-positive tumors 
with MSI (60-62). In addition, the CIMP phenotype accounts for most CIN-negative tumors 
displaying MSI.  
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4 COLORECTAL CANCER 
 
CRC is the second most common cancer in women and the third most common cancer in men 
worldwide, with expected cumulative life time risks of 1.2% for men and 0.65% for women in 
2018. It is 3 to 4 times more common in developed countries than in developing countries (63). 
Geographic differences in incidence display the highest rates in New Zealand, Australia, 
Europe and North America, while South-Central Asia and Africa have the lowest incidences 
(64). Cancer of the colon or rectum is the third most common form of cancer in Sweden, 
constituting up to 11% of newly diagnosed malignancies (65). The lifetime risk of colorectal 
cancer is approximately 5% in Sweden (66). In 2016, the median age for coloncancer was 74 
years in Sweden, and approximately 90% of all patients were above 60 years old (67). 
Between 2007–2011, 4% of all colon cancers and 5% of all rectal cancers were diagnosed in 
patients younger than 50 years (65). The risk of developing cancer increases with age for most 
types of cancer. However, recent international reports have shown a decrease in incidence 
among older age groups, while the incidence has risen in the group with a younger age at onset 
(68, 69).  
Prognosis is highly dependent upon stage of disease at diagnosis, and the 5-year survival rate 
ranges from 90% for tumors detected at the localized stage, to 10% for patients diagnosed with 
distant metastatic cancer. For patients diagnosed between 2005–2009 the survival rates from 
colon cancer were 61% respective 65% for men and women (65). For rectal cancer equivalent 
numbers were 61% and 64% respectively. The relative 5-year survival in Sweden have 
increased in recent decades. The increase can in part be attributed to screening or surveillance 
and improved primary and adjuvant treatments. However, there are global disparities and the 
increased survival is mostly seen in countries with access to modern specialized health care 
and high life expectancy.  
The vast majority of tumors of the colon and rectum are carcinomas, of which approximately 
90% are adenocarcinomas. Examples of adenocarcinomas are the mucinous carcinomas that 
produce mucin (which may be secreted or remain within the cells), non-gland-forming 
adenocarcinomas named signet ring cell carcinoma, and the medullary carcinoma subtype 
which is heavily infiltrated by small lymphocytes. Different morphologic variants come with 
different prognosis. For instance, the subtype signet ring cell carcinomas which has a poor 
prognosis overall, while the medullary adenocarcinoma subtype (often associated with MMR 
protein deficiency and Lynch syndrome) mostly is associated with a relatively favorable 
prognosis (70). There are standardized protocols when classifying tumors. Tumor grading 
describes the grade of differentiation of a tumor; a well differentiated tumor is described as 
low-grade, while a poorly differentiated tumor is described as high grades. The recommended 
staging system for CRC is the TNM system by the American Joint Committee on Cancer 
(AJCC)/Union for International Cancer Control (UICC (71) This system considers the stage of 
the local tumor (T), spread to regional lymph nodes (N) and the occurrence of distant metastasis 
(M).  
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5 HEREDITARY COLORECTAL CANCER  
 
Approximately one third of all CRCs is thought to be related to heritable factors (72). 
Between 5%-10% are caused by high-risk mutations associated with known CRC syndromes, 
while the remaining supposedly are related to less penetrant, more common genetic variants 
(72, 73).  The heritable CRC syndromes can broadly be subclassified into polyposis-associated 
syndromes and non-polyposis syndromes.  
Among the major polyposis-associated syndromes are familial adenomatous polyposis (FAP), 
attenuated FAP (AFAP) and MUTYH-associated polyposis (MAP). In approximately 80% of 
those families, the syndrome is due to a germline mutation in the tumor suppressor gene APC 
or biallelic mutations in the MUTYH (74, 75). The FAP syndrome is characterized by the 
development of hundreds to thousands colorectal adenomas. While approximately 25% of FAP 
is caused by de novo mutations in APC, somatic mosaicism accounts for about 20% of 
unexplained adenomatous polyposis cases (76, 77). In the attenuated form of FAP (AFAP), 
patients have an inherited mutation that only involves the 5′ or 3′ region of the APC gene and 
typically have less than 100 adenomas. In MUTYH-associated polyposis (MAP), patients have 
bi-allelic inactivation of the MUTYH based-excision repair that result in a similar phenotype as 
in AFAP, displaying less than 100 polyps (78). The rarer polyposis-associated syndromes 
include hyperplastic polyposis and the hamartomatous polyposis conditions, including Peutz-
Jeghers syndrome, Cowden syndrome and juvenile polyposis. 
The non-polyposis syndrome Lynch Syndrome, described below, is caused by mutations in 
MMR genes. Noteworthy, adenomatous polyps are also a part of the LS phenotype, albeit with 
much fewer polyps than in the classical polyposis-associated syndromes.  
 
5.1 LYNCH SYNDROME 
Lynch syndrome (LS) is the most common hereditary CRC susceptibility syndrome and arises 
via the MSI pathway. LS was formerly known as hereditary non-polyposis colorectal cancer 
(HNPCC), highlighting the lesser amount of colon polyps in contrast to the polyposis 
syndromes. LS is inherited in an autosomal dominant manner and is defined in terms of having 
a pathogenic germline mutation in any of the DNA MMR genes MLH1 on chromosome 3p21, 
MSH2 on chromosome 2p16, MSH6 on chromosome 2p16 or PMS2 on chromosome 7p22 (79-
86). A minority of LS cases are due to germline deletions in the 3′ end of the EPCAM gene 
located directly upstream of MSH2, resulting in methylation-induced transcriptional silencing 
of MSH2 (87, 88).  
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5.1.1 History of Lynch syndrome 
In the late nineteenth century, pathologist Aldred Warthin at the University of Michigan 
identified several families with colorectal- gastric- and uterine cancer, one of which was the 
family of his seamstress. Dr. Warthin published her pedigree in 1913 and labeled it “Family 
G” (Fig.3) because the family had immigrated from Germany to America (89). Family G 
displayed similarities with two large Midwestern families named N and M, reported in 1966 
by Dr. Henry Lynch (90, 91). Families G, N, M, and other similar families were documented 
and categorized in the 1960s and 1970s, to help define the cardinal features of LS. In 1971 the 
term Cancer Family Syndrome was coined to describe the clustering of cancers in families, and 
after initial skepticism, the hereditary link finally became widely accepted (92). From 1984 the 
terms HNPCC and LS was used interchangeably (93, 94).  
 
 
Figure 3. The pedigree of Family G drawn by dr A.Warthin. Reprinted with permission from A. I Wolf et al., J. 
Coloproctol. (Rio J.) 33:2, 2013, under the Creative Commons Attribution license (CC BY-NC-ND 4.0)(95). 
 
 
The molecular genetics era of LS diagnostics began in 1993, when the LS genes 
MSH2 and MLH1 was mapped to chromosome 2p respective 3p by Peltomäki et al. and 
Lindblom et al. (79, 80). During the same time MSI was identified in LS-associated tumors, 
which was followed by the discovery of other MMR genes including MSH6 and PMS2 (96-
98). The association between PMS2 and LS was described in 1994 but reliable genetic testing 
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for Lynch-associated PMS2 mutations was not offered until later. This was partly due to 
pseudogenes that are highly homologous to the 5′ region of PMS2 complicating the analysis, 
but also to difficulties in identifying mutation carriers because of low penetrance (99-101).  
Today, over 4000 unique germline MMR sequence variants have been deposited to date in the 
InSiGHT (International Society for Gastrointestinal Hereditary Tumors) DNA Variant 
Database, which a databases for LS-associated mutations maintained by The International 
Society for Gastrointestinal Hereditary Tumors (102).  
 
5.1.2 Molecular basis MMR  
The DNA MMR system is involved in the correction of base substitution- and small insertion-
deletion mismatches that arise during DNA replication. It is a well conserved DNA proof 
reading system from bacteria to humans. In prokaryotes, the main MMR proteins shown in 
prokaryotes are MutS and MutL, which are working together in homodimers. In humans, five 
protein homologues to MutS (MSH2, MSH3, MSH4, MSH5 and MSH6) and four protein 
homologues to MutL (MLH1, MLH2, MLH3, PMS1 and PMS2) have been identified (103-
106).  
 
 
 
 
Figure 4. Human DNA MMR protein complexes. Reprinted from P. Peltomäki, Human Molecular Genetics, 
2001,with permission from Oxford University Press (107). 
 
 
The MSH2 protein forms a heterodimer with MSH6 or MSH3, forming the MutSα respective 
the MutSβ complex. Both complexes can recognize mismatched base-pairs such as 
insertion/deletion loops of more than two bases. However, MutSα preferentially recognizes one 
or two-base insertion-deletion loops and single base mispairs while MutSβ recognizes 
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slippages at dinucleotide or longer repeats (Fig. 4). Upon mismatch binding, the MutSα and 
MutSβ complex recruits a protein heterodimer formed by MLH1 coupled with either PMS2, 
PMS1 or MLH3, named MutLα, MutLβ or MutLγ respectively. An excision machinery 
consisting of several other proteins (eg. DNA Helicase, DNA polymerase and DNA ligase) is 
then recruited to the MutS-MutL complex, to remove and synthesize new DNA (107, 108).  
The MSH2 and MLH1 genes are essential for the MutS- and MutL complex to function, and 
have therefore been defined as the major MMR genes, while MSH6, PMS2, 
MLH3 and MSH3 are known as the minor MMR genes (109). 
 
5.1.3 Clinical manifestation and risk reduction  
LS is characterized by genetic heterogeneity and a great variability in phenotypic 
manifestations. A combination of environmental factors and genetic factors may contribute to 
the heterogeneity, which complicates both recognition and management of patients. LS is 
characterized by a high lifetime risk for primarily CRC and ECs, accounting for 3%–5% of all 
CRCs and 2%–3% of all ECs (110-113). In addition, LS is associated with cancers of the ovary, 
stomach, urinary tract (kidney, renal pelvis, ureter and bladder) and small bowel, and less 
frequently cancers of the brain, biliary tract and pancreas (114). Rare skin lesions, such as 
sebaceous lesions and keratoacanthomas, can be indicative of a rare variant of LS named Muir 
Torres (115, 116). Biallelic MMR mutations (BMMRD), with homozygous or compound 
heterozygosity, manifests in a high risk of childhood cancer including hematological, cerebral 
and gastrointestinal tumors (117).  
Cancer risks are commonly stratified according to tumor type, mutated MMR gene and gender. 
As our knowledge increase and diagnostic capabilities improve, estimated risk numbers for 
patients with LS are being adjusted from having up to ~80% risk of cancer by the age of 80, to 
sometimes lower figures depending on mutated gene (118). 
 
5.1.3.1 CRC in Lynch Syndrome 
LS associated CRC often has a proximal colon location and an early age of diagnosis (∼45 
years) compared with sporadic CRC (109). Approximately 7% of the patients have more than 
one cancer by the time of diagnosis, in addition to an increased risk for metachronous CRCs 
(119). The lifetime risk of CRC depends on gender and mutated MMR gene. In a recent report 
based on data from the Prospective Lynch Syndrome Database, the cumulative CRC incidence 
for MLH1 and MSH2 mutation carriers at 75 years of age was estimated to 48% for females 
and 57% for males (120). Equivalent numbers for MSH6 mutation carriers was estimated to 
20% for females and 18% for males, while the risk for PMS2 mutation carriers (male and 
females) was 10%.  
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The incidence of adenomas in LS families is reported to be similar to the incidence of adenomas 
in late-onset colon cancer families without MMR mutation (121, 122). However, it is thought 
that most LS-associated CRC arise from adenomatous polyps, but with an accelerated 
development to carcinoma (~2-3 years vs. ~8-10 years in sporadic CRC) (123, 124). LS-
associated adenomas have a high degree of dysplasia and villous architecture, which together 
with the accelerated progression  to carcinoma would be related to a relatively pronounced risk 
of malignancy (125). Similarly, colorectal tumors associated with LS commonly have 
histologic features like tumor-infiltrating lymphocytes, poorly differentiation with mucinous 
features, or a Crohn's-like lymphoid reaction (126). However, MSI-high tumors generally have 
a better prognosis compared to MSS sporadic tumors and the overall 10-year survival from LS-
associated CRC is high (91%)(127). 
 
5.1.3.1.1 Surveillance and risk reduction 
Colonoscopy screening has proven to significantly reduce CRC incidence in individuals with 
LS, and according to several guidelines the recommended interval of colonoscopy with 
polypectomy is every 1 to 2 years (128-133). Due to the efficacy of control programs, 
prophylactic surgery such as colectomy is not a standard intervention. However, recent data 
suggest that some LS–associated colorectal tumors might develop directly as invasive cancer, 
as opposed to the classical adenoma-to-carcinoma pathway (134). In line with this, it has been 
shown that some patients develop tumors regardless of short surveillance intervals, which has 
started a discussion about optimal intervals and the preventive effect of intense control 
programs (135, 136). Most guidelines agree that screening programs with polypectomy should 
begin at between 20-25 years of age regardless of mutated MMR gene. Noteworthy, since 
lower rates of CRC are reported for MSH6 and PMS2 mutation carriers later initiation of 
screening for those individuals have been discussed (137, 138). 
Data from observational studies indicate a potential role for aspirin in CRC prevention. In a 
multinational prospective study of chemoprevention, the CAPP2 study, MLH1 and MSH2 
mutation carriers were randomly assigned to aspirin or aspirin placebo. The result showed that 
600 mg aspirin per day for a mean of 25 months reduced cancer incidence (139). Further studies 
are dedicated to find the optimal dose and duration for chemoprevention in LS. Thus, for the 
CAPP3 study (http://www.capp3.org/) 3000 MMR mutation carriers will be invited to compare 
100, 300 or 600 mg daily dose of aspirin (140).  
 
5.1.3.2 Gynecological cancer in Lynch Syndrome 
The most common extracolonic tumor in women with LS is EC followed by ovarian cancer, 
with different risks depending on mutated MMR gene. In a recent report from the Prospective 
Lynch Syndrome Database, the cumulative incidence of EC up to 75 years of age was similar 
for MLH1 and MSH2 mutation carriers; 37- 49%, while the risk was 41% respective 13% for 
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PMS2 and MSH6 mutation carriers (141). Equivalent numbers for ovarian cancer was 11% for 
MLH1 mutation carriers, 17 % for MSH2 mutation carriers, and 3% respective 11% for PMS2 
and MSH6 mutation carriers. Previous studies have reported the CRC risk associated with an 
EPCAM mutation to be similar to risks associated with MSH2 mutations, but a lower risk for 
endometrial- or other extracolonic cancer given that the deletion in EPCAM does not extend 
into MSH2 (142, 143).  
The majority of LS-associated ECs are characterized by endometroid histology, similar to 
sporadic EC. However, also non-endometrioid subtypes have been reported, including serous 
carcinomas and clear cell carcinomas (144). MMR mutations increase the risk of different types 
of ovarian cancer of varying proportions between studies, including mucous, endometrioid and 
mixed or clear cell tumors (145).  
 
5.1.3.2.1 Surveillance and risk reduction 
Several studies have investigated the benefit of screening for endometrial and ovarian cancer 
in LS with techniques that include transvaginal ultrasonography, endometrial biopsies or tumor 
marker testing with cancer antigen 125 (CA-125). However, there are no consistent data that 
show an effect on cancer incidence or mortality (146). Screening for EC have shown modest 
sensitivity for detection of endometrial hyperplasia or carcinoma (147) and most guidelines 
recommend patients annual transvaginal ultrasound and endometrial biopsy at age 30 to 35, 
until risk reducing surgery at the completion of childbearing has been done (129, 131, 132).   
Hysterectomy and salpingo-oophorectomy have shown to be efficient in preventing prevent 
endometrial- and ovarian cancer, but the survival benefit remains unclear (148). Noteworthy, 
data from the CAPP2 study indicated that aspirin may also have a preventive effect for 
endometrial and ovarian cancer in LS, but further studies are needed to evaluate this finding 
(140).  
 
5.1.3.3 Other extracolonic cancers in Lynch Syndrome 
LS predisposes to an increased risk of various extracolonic cancer, apart from endometrial and 
ovarian cancer. Sites includes the urothelium-, gastric-, pancreas- , hepatobiliary system, small 
intestine- sebaceous gland and brain (149). According to a recent report from the Prospective 
Lynch Syndrome Database, MSH2 carriers displayed the highest risk among the four MMR-
genes, with approximately 18 % cumulative risk (up to 75 years of age) for ureter and kidney 
cancer in both sexes. Male carriers of a mutation in MLH1 or MSH2 were reported to have 
about 20% risk for cancer in the stomach, small bowel, bile duct, gallbladder and pancreas, 
while female carriers had half of that risk (141). Several studies have analyzed an association 
between LS and prostate cancer or female breast cancer, with different outcome. For instance, 
a previously proposed increase of breast cancer risk in MSH6 and PMS2 mutation carriers has 
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been questioned in a recent study showing cumulative risks across all four MMR genes, 
comparable with general population risks (141, 149-151). Prostate cancer is emerging as part 
of the LS tumor spectrum with lifetime risks reported to be up to 24% for MSH2 carriers, while 
risks are lower for other MMR genes (141, 152, 153).  
A few patient cases have suggested an association of MLH3 variants and brain tumors, and a 
heterozygous MSH3 variant (in combination with a MSH2 variant) with the classical LS-
phenotype (154, 155). In addition, it has been suggested that PMS2 and MSH6 mutation carriers 
might present with a phenotype similar to hereditary breast-ovarian cancer (156). These 
patients are likely to be missed by LS screening, which mainly focuses on the occurrences of 
CRC and EC. 
Currently there is no convincing data to support surveillance for cancer in the urinary tract, 
pancreaticobiliary-, gastric-, small intestinal-, or brain tumors (157). Nevertheless, in the 
presence of a strong family history of a specific cancer, tailored surveillance might be 
considered according to some guidelines (128). 
 
5.1.3.4 Genetic anticipation  
There is a large variation in age of onset between and within families with LS, and genetic 
anticipation (progressively earlier age at onset in successive generations) have been suggested. 
Anticipation was described already in the case report on Family G, where dr. Warthin had 
noticed an earlier age at cancer occurrence in younger generations. Anticipation has also been 
suggested in hereditary cancer syndromes such as familial melanoma, ovarian- pancreatic- and 
breast cancer (158-162). Genetic anticipation is well known neurological and neuromuscular 
diseases, where repetitive trinucleotide DNA sequences that expands during meiosis is a proven 
underlying mechanism (163). However, an alternative mechanism leading to anticipation in 
hereditary cancer is not known at present. In paper II and III we analyze anticipation in Swedish 
respective European families with LS, trying to elucidate whether anticipation in part of the 
clinical picture in those cohorts. Several other reports have been published providing evidence 
for and against anticipation in LS, and the issue remains controversial (164, 165).  
 
5.1.4 Clinical criteria 
In the 1980's when the genetic background to LS was still unknown, the diagnose of LS was 
solely based on family history. In 1990 a collaborative effort was initiated by a group of 
researchers at the International Collaborative Group meeting in Amsterdam, in order to 
standardize clinical criteria for LS. The guidelines referred to as the Amsterdam I Criteria were 
published in 1991 and focused on a strong family history of CRC with a young age of onset 
(166). These criteria were later revised to Amsterdam II (167), to include extracolonic 
manifestations such as cancers of the endometrium, small bowel or pelvic-ureter system. The  
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 guidelines evolved further as the knowledge on molecular and clinical characteristics of LS 
emerged (Table 1). The discovery of microsatellite instability as a hallmark of LS tumors led 
to the understanding that LS is a result of germline MMR gene mutations (50, 98, 168). This 
prompted the development of the Bethesda Guidelines, a list of guidelines to identify patients 
who should be tested for microsatellite instability (169, 170). Later, the Revised Bethesda 
Guidelines was developed to include panels for microsatellite instability testing, directions for 
molecular evaluation of tumors and germline DNA, and a clinical selection of cases (171). 
However, neither the Amsterdam criteria nor Bethesta guidelines are solid screening tests for 
LS. When only clinical criteria is used to identify LS, there is a likelihood of chance clustering 
of cancer within a family as CRC is a relatively common malignancy. While the Bethesta 
guidelines are reported have high true positive rate (sensitivity) but too low true negative rate 
(specificity), computer-based empirical models have been suggested to detect high risk 
individuals, but with a low sensitivity (172, 173). 
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Table 1. Clinical guidelines for identifying Lynch Syndrome. 
 
  
Amsterdam I criteria (166) requires at least three relatives with histologically verified 
CRC, and the following: 
 
• Familial Adenomatous Polyposis has been ruled out 
• One should be first-degree relative to the other two 
• At least two successive generations are affected  
• At least one of the affected is diagnosed <50 years of age 
 
Amsterdam II criteria (167) requires at least three relatives with a Lynch associated 
cancer (colorectal, endometrial, small intestine, ureter, renal pelvis) verified by 
pathologic examination, and the following: 
 
• Familial Adenomatous Polyposis has been ruled out in the CRC cases 
• One should be first-degree relative to the other two 
• At least two successive generations are affected  
• At least one of the affected is diagnosed <50 years of age 
 
Revised Bethesda guidelines (171) for testing of colorectal tumors for microsatellite 
instability (MSI) in families that meet the Amsterdam criteria: 
• At least one CRC is diagnosed <50 years of age 
• Presence of synchronous or metachronous LS- associated tumors* regardless of 
age 
• CRC with the MSI-H histology** diagnosed in a patient <60 years of age 
• CRC or LS-associated tumor* diagnosed under 50 years of age, in at least one 
first-degree relative  
• CRC or LS-associated tumor* in two first- or second-degree relatives, 
regardless of age 
 
* Endometrial, ovarian, gastric, hepatobiliary, or small-bowel cancer or transitional cell 
carcinoma of the renal pelvis or ureter LS-related tumors including colorectal, 
endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain 
(usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas 
and keratoacanthoma in Muir–Torre syndrome, and carcinoma of the small bowel 
** Presence of tumor-infiltrating lymphocytes, Crohn disease-like lymphocytic 
reaction, mucinous or signet-ring differentiation, or medullary growth pattern. 
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5.1.5 Screening for Lynch syndrome 
The two standard tests for screening of colorectal, endometrial or ovarian tumor tissue are the 
MSI and IHC, described below. According to the National Comprehensive Cancer Network 
(https://www.nccn.org/) IHC or MSI-testing is recommended for all patients diagnosed with 
CRC younger than 70 years, and in patients above 70 years if the family meets the Bethesda 
guidelines. MSI and/or MMR IHC detect over 90% of LS patients in sharp contrast to the 
clinical Amsterdam criteria (174) and if either MSI or MMR IHC is positive, the 
recommendation is to proceed with germline DNA testing (175, 176).  
Universal CRC tumor screening have shown to be a cost-effective way to increase in the 
detection rate of LS, and is also recommended for EC (128, 177). In addition, there is data 
indicating that universal tumor screening of ovarian cancer and upper tract urothelial cancer 
might identify Lynch-associated cancers that would be missed using only clinical criteria (178, 
179).  
 
5.1.5.1 MSI assay 
Cells with defective MMR display an inconsistent number of microsatellite nucleotide repeats, 
compared to normal tissue from the same individual. This can be assessed by PCR-based 
amplification of a panel with specific microsatellite markers, to compare the number of repeats 
at each locus, between tumor tissue and normal tissue.  
In order to standardize MSI analysis, the National Cancer Institute (NCI) created a reference 
panel called the Bethesda panel in 1997. The Bethesda panel consists of five standardized loci 
with three dicnucleotide repeats and two mononucleotide repeats (180). However, panels 
containing more mononucleotide markers are reported to have higher sensitivity and specificity 
in CRC diagnostics (181, 182).  
Based on the extent of the genetic instability, MSI can be divided into MSI-High (MSI-H) or 
MSI-Low (MSI-L) (169, 183). Tumors with with ≥30–40 % marker instability are defined as 
MSI-high, while tumors with <30–40 % are MSI-low (169, 184). If the same number of 
repeats is present in each marker in both the tumor and the normal tissue, the tumor is 
microsatellite stable (MSS). 
 
5.1.5.2 Immunohistochemistry 
Loss of MMR protein expression can be detected by immunohistochemistry (IHC), which also 
is an indirect way to detect microsatellite stability (although not specific for LS). The principle 
of IHC is to use antibodies to bind antigens within tumor tissue sections and visualize the 
antibody-antigen interaction by any of various techniques for tissue staining. 
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IHC is a well-accepted initial screening test for LS, where antibodies to the MMR proteins 
MLH1, MS2, MSH6, and PMS2 are used to determine expression of their corresponding genes 
in CRC and EC. The protein expression of the minor MMR genes depend the expression of 
MLH1 or MSH2 (185). Thus, if there is a mutation in any of the minor MMR genes, the major 
MMR genes are still expressed.   
IHC relies on evaluation of staining patterns and intensity, and therefore requires experience 
on the part of the pathologist to interpret. For a clearly positive or negative result, the 
interpretation of IHC is straightforward. However, when there is ambiguous staining of the 
tissues and weak protein expression, results may be inconclusive (186). 
 
5.1.5.3 Founder mutations 
Founder mutations originates from a single ancestor (or are introduced into a population by a 
single individual) who passes it on to succeeding generations. While some founder mutations 
are detected in only a few families with a single origin, others are frequently found in specific 
geographic regions or countries (187). Founder mutations may affect the prevalence of LS in 
certain populations and influence the relative proportion of specific mutations. Therefore, 
founder mutations represent a useful tool in genetic screening, as testing for them as a first step 
in relevant populations may lower the cost of molecular diagnosis.  
For instance, an exon 16 deletion in MLH1 in the Finnish population probably dates back over 
1000 years. Together with another Finnish founder in MLH1, c.454-1G>A, those mutations 
accounts for more than 50% of all LS in Finland (188, 189). In the Ashkenazi Jewish 
population, the majority of LS cases appear to be caused by the mutations 
c.3959_3962delCAAG and c.3984_3987dupGTCA in MSH6 and the mutation c.1906G>C in 
MSH2 (190, 191). Another MSH2 mutation (c.942+3A>T) has been detected in 27% of LS 
cases in the province of Newfoundland in Canada. This mutation is a common MMR mutation 
and repeatedly arises de novo because of 26 consecutive adenines in the DNA strand, leading 
to DNA misalignment (192). Nevertheless, mutation carriers in Newfoundland share a 
common haplotype that is not present in carriers from England, Japan Hong Kong or Italy. 
Thus, the MSH2 c.942+3A>T presents a founder effect in this population (193, 194). At least 
three Swedish MMR founder mutations have previously been identified the MMR genes (195, 
196). In paper I, we analyze the presumptive Swedish founder mutation c.2059C>T in MLH1, 
identified in ten families of Swedish origin.  
 
5.1.5.4 Next-Generation Sequencing 
Identification of germline MMR mutations is critical for confirmation of LS and possibly the 
clinical management due to varying risks associated with different MMR mutations (197). In 
addition, it has been suggested that patients with MMR deficiency might benefit from 
immunotherapy (Fig. 5). Fortunately, the detection of LS has evolved from only using clinical 
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criteria to tumor-based screening with germline confirmation, and strategies may evolve further 
when costs for mutation screening drop further.  
During the last decade next-generation sequencing of multigene panels for germline testing has 
emerged, as an alternative to traditional syndrome-specific gene testing. This has, though, 
raised the issue of management of unexpected findings (198). In addition, a number of the 
reported mutations are missense, silent or intronic variants with uncertain pathogenicity, and 
are therefore classified as Variants of Uncertain Significance (VUS)(199). The InSiGHT 
Variant Interpretation Committee (VIC) provides interpretation of variants, with classification 
criteria available at https://www.insight-group.org/criteria/. To facilitate the management of 
families with suspected LS, a collaborative effort was undertaken in 2014, to reclassify the 
MMR variants deposited in the InSiGHT database (102). 
 
 
 
Figure 5. Management of patients with LS. Reprinted with permission from Durato et al. Oncol Lett. 2019 Mar; 
17(3), under the Creative Commons Attribution license (CC BY-NC-ND 4.0)(200). 
 
 
 
5.1.6 Epidemiology  
The heterogeneity in phenotype and penetrance of LS poses challenges in establishing 
population-based prevalences, however it appears that LS is relatively common across a 
diversity of ethnicities. Results from a recent study suggests that the prevalence of LS is higher 
in the European population compared to non-European ancestry populations (201). Minority 
populations are underrepresented in LS studies and prevalence data in those populations are 
therefore limited and may be biased. Moreover, despite similar rates of colorectal tumor testing, 
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minority patients are reported to be less likely to be referred to genetic counselling and testing 
(202).  
Prevalence numbers of LS and MMR germline mutations varies depending on if patients are 
ascertained based on family history of CRC/EC, or if measurements are made in the general 
population. For the most part, calculations have been made in the context of a family history 
with cancer, and LS-associated CRC and EC then accounts for 2% and 3% of the total cases 
respectively (198, 203-208). The majority of germline mutations have been detected in MLH1 
and MSH2, while germline mutations in MSH6, PMS2 and EPCAM are represented in fewer 
LS-cases (198, 203, 205, 209-211). However, recent epidemiologic data indicates that LS-
associated mutations are less penetrant and more common in the overall population than 
previously estimated. By analyzing clinical data from families of 5744 CRC cases 
(probands) in the Colon Cancer Family Registry (https://www.coloncfr.org/), Win et al. 
estimated the population prevalence to be 1/1946 for MLH1 mutations, 1/2841 for MSH2 
mutations, 1/758 for MSH6 mutations, and 1/714 for PMS2 mutations (212). Altogether, the 
estimated the population prevalence for carrying any MMR mutation was estimated to be 
1/279, making LS one of the most common heritable cancer syndromes. Noteworthy, mutations 
in PMS2 and MSH6 was reported to be the most common among MMR-mutations, in spite of 
being relatively uncommon among patients ascertained with LS based on personal history of 
cancer. This is in line with studies that suggest that carriers of PMS2 and MSH6 mutations have 
lower cancer risk or later age at onset, compared to MLH1 and MSH2 mutation carriers (101, 
213-217). Further, this has led some authors to suggest modified guidelines for genetic 
counseling and surveillance for those genotypes (141). 
 
5.1.7 Genetic counselling   
Identification of patients with LS has greatly improved over the last two decades, still the 
syndrome is underdiagnosed, not only in minority populations (218). It is of utmost importance 
that clinicians recognize affected families, to offer genetic counselling and genetic screening, 
as well as surgeries and therapy to reduce mortality and morbidity.  
Individuals with LS have no distinguishing traits other than an increased incidence of cancer. 
Due to a lack of specific phenotypic features, LS can be difficult to diagnose. Therefore, a 
comprehensive family history of all cancer among relatives, with attention paid to the cardinal 
features of LS, is important in facilitating the process. This allows for the identification of 
patterns of disease or possible differential diagnosis, for both patient and family. Ideally, a 3- 
to 4-generation family pedigree can be obtained including relatives with their current age or 
age at death, to identify patterns of inheritance. Additionally, both maternal and paternal ethnic 
backgrounds are of interest with particular attention to e.g Ashkenazi Jewish ancestry because 
of founder mutations in this population.  
One cornerstone in genetic counselling is to establish an effective process for education 
regarding the inheritance and should focus on unbiased information and non-directive support 
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in the patient´s decision-making process (219). Individuals of reproductive age might benefit 
from information regarding prenatal testing options, including preimplantation genetic 
diagnosis (220).  
The amount of information that reaches at-risk relatives depends upon how effective the 
intrafamilial communication is. Most patients notify first-degree family members (children, 
parents, siblings) but are less likely to inform family members that are more distant, because 
of lack of closeness and concerns that the information will not be understood (221). Thus, one 
challenge is to optimize the process of notification of at-risk relatives and subsequent genetic 
testing. Due to this, resources to assist patients in the process of notifying at-risk relatives, 
seeking appointment with genetic counselors and possibly give informed consent is under 
development in several countries.  
One challenge to patient uptake is the significant heterogeneity among patients with LS, some 
of which can be attributed to which of the MMR genes is mutated. According to recent studies, 
aging patients display distinct patterns of cancer risk and survival depending on MMR mutation 
(137), information that should be taken into consideration during counselling. Adding to the 
complexity of LS, there is heterogeneity among family members carrying the same mutation. 
This possibly illustrates that environmental or polygenic factors and possibly genetic 
anticipation may influence phenotypic expression, something that we address in our study of 
anticipation in paper II and III.  
Clearly, it takes a concerted effort from both patients and clinicians to improve current 
approaches to the diagnosis and prevention of LS but in the long term, lessons learned can be 
applied to other hereditary conditions.  
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6 AIM OF THE THESIS 
 
 
The overall aim was to study the clinical picture in Swedish LS families, specifically the 
tumor spectrum, if the age at cancer onset is decreasing in successive generations, and a 
Swedish founder mutation. We hope that this work will contribute to further research, that in 
the long run improve the clinical management of individuals with LS. Future improvements 
that would be of high value is increased effectiveness of surveillance, by individually 
adjusted control programs and personalized risk estimations. 
 
  
 
Specific aims in this thesis; 
 
  
- Compare disease associated haplotypes in families from Sweden, Germany and 
France, all carrying the frequent MLH1 mutation c.2059C>T, in order to elucidate if 
this mutation act as a founder mutation in Sweden.  
 
 
- Investigate if genetic anticipation is part of the clinical picture in a Swedish cohort of 
LS families, as well as in a larger international cohort of PMS2-mutation carriers.  
 
 
- Characterize the tumor spectrum, excluding CRC- and ECs, in Swedish LS families. 
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7 MATERIALS AND METHODS 
 
7.1 PAPER I  
Patients in the haplotype analysis: Eight Swedish families that were identified at the 
Karolinska University Hospital in Stockholm, carrying the MLH1 c.2059C>T mutation, were 
enrolled in the study. In addition, one Finnish family with Swedish descent, three families from 
Germany and one family from France were included. In the Swedish families, 11 patients 
participated altogether. From the other families, one individual from each family participated, 
thus a total of 20 patients were analyzed.   
Patients in prevalence study: The case cohort was composed of 2982 CRC patients that 
underwent surgery in Stockholm or Uppsala county between years 2004-2009. The control 
cohort was composed of 1610 anonymous blood donors from the same geographic region as 
the CRC patients, including 448 healthy spouses to CRC patients. 
TaqMan analysis in prevalence study: Screening of the c.2059C>T mutation in the case 
cohort and control cohort was performed using TaqMan SNP Genotyping Assay.  
Haplotype analysis: For genotyping, 19 polymorphic microsatellite markers surrounding the 
MLH1 gene. Microsatellites were amplified using PCR and analyzed using electrophoresis and 
a manually determined. 
 
7.2 PAPER II 
Patients: Participants were recruited from the regional department of Clinical genetics in 
Umeå, Uppsala, Stockholm, Linköping, Göteborg or Lund, where they had received genetic 
counselling and genetic testing between 1990-2013. In this population-based cohort, 1003 
mutation carriers from 239 families with pathogenic MMR variants were identified with 
sufficient pathological and medical information to enroll in the study. Altogether, 96 MLH1 
families, 89 MSH2 families plus one EPCAM-deletion family, 39 MSH6 families, 12 PMS2 
families, and 2 families with mutation in both MLH1 and PMS2 were included.   
Statistic methods: The patient follow-up period was defined as the time from birth until the 
time of first cancer diagnosis or censoring. Two models were used; a normal random effects 
model (NREM), and an extension of the Cox proportional hazards model with a family-level 
random effect (COX-R). NREM calculates the anticipation effect in mean change in age at 
diagnosis between consecutive generations while COX-R calculates the effect of anticipation 
between generations as a log-hazard ratio. Both models take generation (coded with respect to 
oldest observed generation in each family), sex and mutational status into account. All analysis 
were done in the R software package (222). 
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7.3 PAPER III 
Patients: Data from 157 families with a total of 637 family members divided over three 
generations was collected from clinical genetic departments in the Netherlands, Norway, 
Germany, Sweden, Denmark, and Spain between the years 2009-2017. Clinical and pathologic 
diagnoses as well as polypectomy, and hysterectomy were conﬁrmed using patient records. Not 
all family members were genetically tested but mutation probabilities were calculated from 
kinship coefficients, resulting in an estimated number of 360 mutation carriers in the sample. 
Method: Within the families there were a total number of 123 CRCs. Genetic anticipation was 
estimated as the effect of generation on a person's hazard for age at first cancer diagnosis using 
a cox-type random effects model in the R package survival. The effect of sex and year of birth 
was included in a second adjusted analysis. Ascertainment bias was controlled by including 
individuals who had been at risk for at least 65 years and excluding the probands. As not all 
individuals were genetically tested, mutation probabilities based on kinship were used to avoid 
possible testing bias.  
 
7.4 PAPER IV 
Patients:  Families were recruited from five of six regional department of Clinical genetics in 
Uppsala, Stockholm, Linköping, Göteborg or Lund where they had received genetic 
counselling and genetic testing. In total, 235 LS families participated, of which 445 individuals 
had a pathogenic variant, 343 were obligate carriers and 265 individuals were assigned a 50% 
carrier probability (MLH1 n = 97, MSH2 n = 87, MSH6 n = 37 and PMS2 n = 14). 
Statistical method: The data was stratified for gender, primary cancer, age and mutated gene. 
The relative proportions of specific cancer types in relatives to the index patients were 
compared to the relative proportion in the general population, using data from the Swedish 
Cancer registry as reference. Comparison was done at two different time points (1970 and 
2010) to compensate for difference in incidence rates over time. The population distribution of 
cancer was weighted by the age and sex of cases in the data (relatives to index cases). Using 
binominal distributions, confidence intervals (95%) were calculated for each cancer site and 
transformed to proportions (number of cancers at each site/ total number of cancers). The 
confidence intervals were then compared with corresponding confidence intervals for the 
general population. 
Categorical data was tested for heterogeneity with chi-square tests and p-values were calculated 
using Monte Carlo simulations. All calculations were performed in the R software package (R 
core team, 2012). 
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8 RESULTS AND DISCUSSION 
 
8.1 PAPER I 
In the prevalence study, one individual in the cohort of 2982 CRC cases was carrying the 
mutation, a patient who subsequently was included in the haplotype study. There were no 
carriers of the MLH1 c.2059C>T mutation among the 1610 normal controls, which was 
expected as the global carrier status in the normal population is approximately 1/25.100 
according to gnomAD database (https://gnomad.broadinstitute.org/).  
When analyzing the haplotype in the eight Swedish families and the Finnish family with 
Swedish ancestry, a shared region of about 0.9–2.8 Mb was identified. Crossovers were seen 
in two different families at the 3´ or the 5´end respectively. The downstream and upstream 
haplotypes in both families were consistent with a common haplotype, which might imply 
that the shared haplotype is larger than 2.9 Mb, and that there have been mutation events in 
the markers rather than recombination events in the two differing families. Mutation carriers 
in the French and German families did not share this haplotype, indicating that variant is a 
founder mutation in Sweden. The probable origin is in the north of Sweden since the earliest 
verified case in the Swedish families was in a geographical area in the middle-north of Sweden 
in the nineteenth century. One Swedish family and the Finnish family had ancestors from the 
northern part of Sweden. In addition, there are two additional families in the northern part of 
Sweden previously identified with this mutation, but samples from these families were not 
available when we did the haplotype analysis.  
The MLH1 c.2059C>T mutation thus act as a founder in the Swedish population, but is also 
found in Europe, Asia and Australia, indicating that this is a recurring mutation globally albeit 
with a very low allele frequency. The effect of genetic drift is more pronounced in isolated 
populations than in heterogeneous populations. Still, mutations occurring in hotspots in the 
DNA sequence can be prevalent in diverse populations, and at the same time display a 
founder effect in populations, as heterogenous as the Swedish.  Other examples of recurring 
founder mutations are a MSH2 mutation found in Portugal, and one MSH2 mutation in 
Newfoundland (223, 224). Both mutations displayed a founder effect in respective country but 
were also found in other populations in Europe or Asia on different haplotypes. Another 
founder mutation that occur in a heterogenous populations is a MLH1 mutation detected in 
America and Italy, but on different haplotypes (225). 
Founder mutations and recurrent mutations could provide a tool in trying to identify the cancer 
risk attributable to specific mutations. In addition, single nucleotide polymorphisms present in 
shared haplotypes might provide valuable information when striving to predict risk in specific 
LS families. In line with this, a MLH1 intron 14 founder mutation identified in the Danish 
population has been suggested to be associated with a reduced risk of extracolonic tumors(226), 
while a nontruncating MLH1 missense mutation identified in Italy, was reported to causes a 
particularly aggressive phenotype and being frequently associated with extracolonic 
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cancers(227). Moreover, a recurrent MSH2 mutation at an intron 5 splice site is reported to be 
associated with a higher risk for CRC in male carriers, while female carriers seemed to have 
arelatively higher risk for ovarian cancer (228, 229). Optimally, both mutated MMR gene and 
phenotype observed in each family is taken into account when designing surveillance 
programs, and evaluation of the specific cancer risk attributable to specific mutations may be 
helpful in this work.  
 
8.2 PAPER II AND III 
In paper II, a total of 719 confirmed mutation carriers were diagnosed with at least one Lynch-
associated cancer during the follow-up period, of which the first diagnosis was used in the 
analysis. The median age of first diagnosis in the whole cohort was 51 years (95% CI: 50–53). 
Stratified by mutated gene, it was 49 years in both MLH1 and MSH2 patients and 58 and 67 
years, respectively, for MSH6 and PMS2 patients.  
Both NREM and COX-R models suggest the presence of anticipation; a 2.1 year decrease in 
the age of diagnosis per generation and a hazard ratio of 1.19 between consecutive generations 
respectively, across the whole cohort. When the patients were stratified accorded to mutated 
gene, the confidence intervals for an anticipation effects of MSH2 and PMS2 lie far from their 
null values, while the effect of anticipation in MLH1 and MSH6 is less evident (Table 2).  
 
Table 2. Gene-specific effects of anticipation per generation in paper II. 
 NREM COX-R 
MLH1 
Estimate 
Wald p-value 
Hazard ratio 
 
-1.76 
(0.044) 
 
0.127 
(0.133) 
1.13 
MSH2 
Estimate 
Wald p-value 
Hazard ratio 
 
-2.55 
(0.003) 
 
0.284 
(0.001) 
1.33 
MSH6 
Estimate 
Wald p-value 
Hazard ratio 
 
-1.10 
(0.366) 
 
-0.005 
(0.965) 
0.99 
PMS2 
Estimate 
Wald p-value 
Hazard ratio 
 
-7.33 
(0.014) 
 
0.618 
(0.052) 
1.86 
 
 
In paper III, the analysis included 637 individuals from 152 families, with 123 CRCs in total. 
The median age of first CRC diagnosis was 70 years with a standard deviation of 12.94 (other 
Lynch-associated tumors were not part of the analysis). Not all individuals were genetically 
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tested, therefore mutation probabilities based on kinship were used to avoid possible testing 
bias. After weighing, the estimated number of mutation carriers in the sample was 360.  
Genetic anticipation was estimated as the effect of generation on a person's hazard for age at 
first cancer diagnosis, using a similar hazard model as in paper II, the cox-type random effects 
model. The effect of sex and year of birth was included in a second adjusted analysis. Hazard 
ratios were calculated by the Cox-type random effects model and shows an increase in the 
crude analysis for the second and third generation (Table 3). When corrected for gender and 
birth cohort, hazard ratios decreased and was no longer statistically significant. The adjusted 
analysis indicated that year of birth affected the result, equaling a roughly 5% increase of risk 
for every year (HR = 1.05; 95% CI = 1.02–1.07). 
 
Table 3. Anticipation effects of per generation in paper III. 
COX-model 
PMS2-families 
Crude analysis  
HR (95% CI) 
Analysis adjusted for gender 
and birth cohort (95% CI) 
 
Generation 1 
Generation 1 
Generation 1 
 
reference 
2.24 (1.16–4.33)  
2.64 (1.08–6.46) 
reference 
1.30 (0.65–2.62 
1.07 (0.41–2.84) 
 
When studying genetic anticipation, various biases might cause a false anticipation effect. In 
paper I, an anticipation effect was seen in Swedish families with MSH2 and PMS2 mutation, 
with the most prominent effect in families with PMS2-mutation. When a cohort with European 
families with PMS2-mutation were analyzed in paper III, the anticipation effect was not 
significant when corrected for birth cohort. A cohort effect has been a proposed bias in other 
studies of anticipation, and the phenomenon might be difficult to differentiate from 
anticipation. However, Boonstra and collegues published a review of statistical methods used 
in studying anticipation, and confirmed the presence of anticipation in LS families in the 
Danish HNPCC-register using the most common methods (230). Further, a germline founder 
mutation in MSH2 was reported to be clearly associated with anticipation in 4 LS families, 
in the absence of a birth cohort effect (231). In addition, a study of a large Danish LS cohort 
reports a progressive decrease in age at onset excluding birth cohort effects bias (232).  
Other biases to take into account when analyzing anticipation is be the rising incidence of 
CRC, specifically in younger patients, that might be reflected also in the group of LS patients. 
Together with possibly underreported diagnosis in older generations, today’s improved 
screening with cascade testing of family members, those factors likely affect age at diagnosis 
in successive generations. The research design and statistical methods applied in paper II at 
the time was superior to many previous studies, however it has shortcomings compared to 
paper III, and vice versa. First of all, the strong anticipation effect found for PSM2 in paper II 
might be questioned since there were only 12 PMS2 families in the total sample, compared 
with 152 PMS2 families in paper III. Still, the result in paper II reached statistical 
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significance, but results from studies with smaller sample sizes may in general be interpreted 
with caution. In addition, the larger sample size in paper III did allow for the exclusion of 
probands reducing bias of including index patients.  
Discrepancies in result between different studies may be due to the different study designs 
and different inclusion criteria. Both study II and III calculated the effect of generation on an 
individual’s hazard of cancer diagnosis, in addition to a normal random effects model used in 
paper II. Paper II included confirmed mutation carriers in MLH1, MSH2, MSH6 and PMS2, 
while paper III assigned participants probabilities of carrying a mutation in PMS2 (the 
estimated number of carriers were 360). Thus, the cohort in paper III consisted exclusively of 
families with the PMS2 mutation, as opposed to paper II that included families with different 
mutations. The anticipation effect for MSH2 in paper II is therefore not in conflict with the 
results in paper III. Notably, 90 families with MSH2 were included in the study thus the 
findings do not suffer from the same risk of biases as the PMS2 cohort.  
In contrast to triplet expansions, which is a well-known underlying mechanism to anticipation 
in neurological and neuromuscular diseases, the mechanism behind anticipation in hereditary 
cancer is largely unknown. In summary, a clinical observation of anticipation and statistical 
analyses in different studies cannot indicate the underlying mechanism in hereditary cancer. 
Until a possible molecular mechanism for genetic anticipation is identified, it will be difficult 
to elucidate whether the anticipation is due to genetic effects or sampling errors. Today, 
screening protocols for LS patients recommend starting endoscopic surveillance between 20-
25 years of age, or 10 years before the earliest cancer diagnosis in the family, which may be 
sufficient if one would take anticipation into consideration.  
 
8.3 PAPER IV 
Several previous reports have analyzed the tumor spectrum in LS and in this retrospective 
study, we define the relative tumor frequencies in a nationwide Swedish cohort of LS families, 
excluding the most common cancers CRC and EC. Compared to the reference population from 
the Swedish Cancer Registry, individuals of both sexes in our cohort had a higher proportion 
of gastric cancer, small bowel cancer and urinary tract cancer. In female mutation carriers, the 
proportion of ovarian cancer and non-melanoma skin cancer was increased compared to the 
reference population.  
When stratified by mutated gene, the number of PMS2 carriers with non-colorectal/non-ECs 
was too low for further analysis. However, MLH1 carriers had an elevated frequency of gastric, 
pancreas and small bowel cancer, and MSH2 carriers had an elevated proportion of gastric-, 
small bowel, urinary tract, non-melanoma skin (only in female carriers) and ovarian cancer. 
The proportion of gastric cancer in MSH6 carriers was higher compared to the general 
population but the difference was not statistically significant.  
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When dr. Warthin initially described LS kindreds he noted predominantly gastric and ECs, and 
to a much lesser extent CRC (only two patients had CRC).  However, the distribution of LS-
associated malignancies seems different today and an alternative picture also about 
extracolonic tumors is evolving. According to the Swedish cancer registry, the annual 
incidence for gastric cancer in the general population has decreased between 1970 and 2010, 
something that is reflected also in LS tumor spectrum. Of note, there are differences between 
Eastern and Western populations with regard to gastric cancer in LS patients. It is reported to 
be the most common or second most common extracolonic malignancy in Chinese and 
Brazilian LS populations, compared to western population where it presents as the third or 
fourth most common malignancy (233, 234). 
MLH1 and MSH2 carriers in both sexes had an increased frequency of small bowel cancer in 
our cohort, compared to the reference population. The incidence of small bowel cancer varies 
in different studies, with numbers between 0.6-7% (235, 236). Despite a relatively low risk, it 
is clearly elevated in association with LS compared to the normal population w. In a recenr 
prospective study, cancers of the upper gastrointestinal cancers (including stomach, 
duodenum, bile duct, gall bladder or pancreas) were altogether diagnosed predominantly at 
old age with highest risks in MLH1 and MHS2 carriers (21 % risk and 10% risk 
respectively)(141). In MSH6 carriers the risk for upper gastrointestinal cancers was 7%, i.e 
still higher than the normal population, which was not confirmed in our Swedish cohort.  
Ovarian cancer is one of the most common gynecologic cancers globally with a cumulative 
risk up to 75 yrs of age of 1.06% (5), after cervical and uterine cancer(1). Ovarian cancer har a 
much lower prevalence compared to breast cancer, but it three times more lethal and has the 
worst prognosis among gynecological cancers in (237). In the Swedish female LS cohort, 
ovarian cancer was elevated in the MSH6 and MSH2 group, but not in the MLH1. 
The same trend was also seen in a large prospective study where MSH6 and MSH2 have higher 
frequency of ovarian cancer compared to MLH1(137). Incidences for ovarian cancer were 17% 
and 13% in MSH2 and MSH6 respectively while 10% in MLH1 carriers and occurred mainly 
premenopausally, similar to our study. Female carriers overall also had elevated frequencies of 
urinary tract cancer, as did MSH2 mutation carriers when the cohort was stratified by gene. 
Cancer of the upper urinary (urinary bladder, ureter or kidney) tract is a well described 
malignancy of LS with recently reported risks of 8.0%, 24.9% and 11.0% in MLH1, MSH2 
and MSH6 carriers respectively (137). However, numbers vary between different studies and 
several reports indicate that MSH2 mutations account for a majority of UC (238-240). Non-
melanoma skin cancer also had an increased proportion in the female group of LS patients, and 
in the group of MSH2 carriers.  
Among  skin cancers described in LS cohorts the most notable is that of the Muir-Torre which 
often comes with at least one sebaceous neoplasms and typically at least one gastrointestinal 
or urological malignancy(241). Regarding pancreatic cancer, most cases are sporadic, but up 
to 10% are estimated to be related to hereditary factors(242). In the Swedish cohort we could 
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see a relative increase only in MLH1 carriers. A similar trend was shown in a recent 
prospective study, with a life time risk of 6,2 associated with MLH1, while risks associated 
with MSH2 and MSH6 mutations amount to 0.5% and 1.4% respectively(137). Conversely, 
other reports suggest that mutations in MSH2 are responsible for the majority of lynch 
associated pancreatic cancer, underscoring that there are potential variable phenotypes for 
different germ-line MMR mutations (243).  
In summary, the tumor spectrum apparently varies depending on mutated gene, gender and 
age, in addition to the influence of individual and environmental factors. Also, the incidence of 
LS was thought to be relatively rare, a belief that is slowly changing. The number of tumor 
types included in LS is growing, allowing diagnostic criteria and surveillance to be a subject 
of discussion. This, in addition to variable ages at onset, is of high relevance during genetic 
counseling and in the strive for precision surveillance programs. 
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9 FUTURE PERSPECTIVES 
 
Even with intense surveillance, colorectal cancer is reported to develop in between controls, 
in some patients. Recent data showed that the stage of CRC and interval since last 
colonoscopy were not correlated in patients, and despite surveillance with colonoscopy and 
polypectomy the lifetime risk of CRC (in MLH1 and MSH2 carriers) was approximately 
50%. This raises questions regarding the molecular mechanisms behind the development of 
carcinomas. Important future research would aim at the different carcinogenetic 
mechanisms as opposed to the traditional adenoma-carcinoma pathway. In addition, case 
reports of spontaneous regression of sporadic CRC displaying MSI, which encourages 
future research on immune responses that might act in removing developing precancerous 
cells. 
The Swedish MLH1 founder c.2059C>T identified in paper I did not segregate perfectly 
with disease in the investigated families, and other sequence variants (genetic modifiers) 
are likely influencing the penetrance of the known mutation. In the aim of improving the 
clinical surveillance of patients, it would be interesting to extend the mutation screening 
from the known pathological founder mutation to include other genetic modifiers in the 
screening of those families. Newer techniques, such as whole-genome sequencing (WGS) 
or whole-exome sequencing (WES) should preferably be used for this purpose. 
It would also be interesting to extend the analysis in other MMR mutations displaying very 
different penetrance in different patients. For instance, PMS2 mutations are mostly detected 
in families not fulfilling Amsterdam criteria and were recently suggested to have no 
increased risk for CRC, endometrial, or ovarian cancer before the age of 50. Nevertheless, 
there are a number of PMS2-carriers reported with early-onset cancers. This highlights the 
variability of PMS2 penetrance and possible interaction effects with low penetrance 
mutations. If possible, identifying families with shared haplotypes might facilitate the 
search for modifying variants.  
Identification of patients with LS has greatly improved over the last two decades, still the 
syndrome is underdiagnosed. One underlying factor is the phenotypic heterogeneity in LS, 
which is proposed to be influenced of both environmental and genetic factors. The 
suggested genetic anticipation in Lynch syndrome is debated, with some studies reporting 
anticipation while the effects have been ambiguous or absent in others. Recent studies 
adopting advanced research design and robust statistical methods still show conflicting 
results, which also is illustrated in the different results found in paper II and III. Possible 
future studies should include subjects with proven mutations in all the four MMR genes, 
with biases such as cohort bias taken into account. Future studies also need to include larger 
representative samples, preferably pooled from several centers and countries. 
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